CARA
Income statement / Annual
Last year (2023), Cara Therapeutics, Inc.'s total revenue was $20.97 M,
a decrease of 49.92% from the previous year.
In 2023, Cara Therapeutics, Inc.'s net income was -$118.51 M.
See Cara Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$20.97 M
|
$41.87 M
|
$23.03 M
|
$135.08 M
|
$19.89 M
|
$13.47 M
|
$911,000.00
|
$86,000.00
|
$3.80 M
|
$3.18 M
|
| Cost of Revenue |
$6.17 M |
$7.27 M |
$1.55 M |
$107.07 M |
$113.16 M |
$75.53 M |
$48.52 M |
$49.25 M |
$21.22 M |
$15.07 M |
| Gross Profit |
$14.79 M |
$34.60 M |
$21.47 M |
$28.01 M |
-$93.28 M |
-$62.06 M |
-$47.61 M |
-$49.17 M |
-$17.42 M |
-$11.89 M |
| Gross Profit Ratio |
0.71 |
0.83 |
0.93 |
0.21 |
-4.69 |
-4.61 |
-52.26 |
-571.71 |
-4.58 |
-3.74 |
| Research and Development
Expenses |
$108.51 M
|
$91.88 M
|
$82.70 M
|
$107.85 M
|
$113.82 M
|
$75.53 M
|
$48.52 M
|
$49.25 M
|
$21.22 M
|
$15.07 M
|
| General & Administrative
Expenses |
$27.65 M
|
$30.26 M
|
$29.41 M
|
$21.75 M
|
$17.75 M
|
$15.32 M
|
$11.87 M
|
$9.23 M
|
$7.77 M
|
$6.18 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$27.65 M
|
$30.26 M
|
$29.41 M
|
$21.75 M
|
$17.75 M
|
$15.32 M
|
$11.87 M
|
$9.23 M
|
$7.77 M
|
$6.18 M
|
| Other Expenses |
$130,000.00 |
$2.06 M |
$642,000.00 |
$97,000.00 |
$4.49 M |
$2.98 M |
$1.16 M |
$652,000.00 |
$101,000.00 |
$361,000.00 |
| Operating Expenses |
$142.46 M |
$122.14 M |
$112.11 M |
$129.70 M |
$131.57 M |
$90.85 M |
$60.40 M |
$58.49 M |
$28.99 M |
$21.25 M |
| Cost And Expenses |
$142.46 M |
$129.40 M |
$112.11 M |
$129.70 M |
$131.57 M |
$90.85 M |
$60.40 M |
$58.49 M |
$28.99 M |
$21.25 M |
| Interest Income |
$0.00 |
$2.06 M |
$603,000.00 |
$2.06 M |
$4.49 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$604,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$126,000.00 |
| Depreciation &
Amortization |
$259,000.00
|
$1.67 M
|
$1.55 M
|
$1.01 M
|
$799,000.00
|
$370,000.00
|
$495,000.00
|
$1.47 M
|
$839,000.00
|
$783,000.00
|
| EBITDA |
-$117.65 M
|
-$83.80 M
|
-$88.19 M
|
$5.59 M
|
-$111.48 M
|
-$77.01 M
|
-$58.99 M
|
-$56.94 M
|
-$24.35 M
|
-$17.29 M
|
| EBITDA Ratio |
-5.61 |
-2.09 |
-3.87 |
0.04 |
-5.62 |
-5.75 |
-65.3 |
-679.07 |
-6.62 |
-5.69 |
| Operating Income Ratio
|
-5.79
|
-2.09
|
-3.87
|
0.04
|
-5.62
|
-5.75
|
-65.3
|
-679.07
|
-6.62
|
-5.69
|
| Total Other
Income/Expenses Net |
$2.98 M
|
$2.06 M
|
$642,000.00
|
$2.33 M
|
$4.49 M
|
$2.98 M
|
$1.16 M
|
$652,000.00
|
$101,000.00
|
$126,000.00
|
| Income Before Tax |
-$118.51 M |
-$85.47 M |
-$88.44 M |
$7.72 M |
-$107.19 M |
-$74.40 M |
-$58.33 M |
-$57.75 M |
-$25.09 M |
-$17.95 M |
| Income Before Tax Ratio
|
-5.65
|
-2.04
|
-3.84
|
0.06
|
-5.39
|
-5.52
|
-64.03
|
-671.49
|
-6.6
|
-5.65
|
| Income Tax Expense |
$0.00 |
-$2.06 M |
-$248,000.00 |
-$691,000.00 |
-$816,000.00 |
-$389,000.00 |
-$204,000.00 |
-$468,000.00 |
-$397,000.00 |
-$201,000.00 |
| Net Income |
-$118.51 M |
-$83.41 M |
-$88.19 M |
$8.41 M |
-$106.37 M |
-$74.01 M |
-$58.13 M |
-$57.28 M |
-$24.69 M |
-$17.75 M |
| Net Income Ratio |
-5.65 |
-1.99 |
-3.83 |
0.06 |
-5.35 |
-5.5 |
-63.8 |
-666.05 |
-6.49 |
-5.59 |
| EPS |
-2.19 |
-1.55 |
-1.74 |
0.18 |
-2.49 |
-2.06 |
-1.86 |
-2.1 |
-1 |
-0.85 |
| EPS Diluted |
-2.19 |
-1.55 |
-1.74 |
0.18 |
-2.49 |
-2.06 |
-1.86 |
-2.1 |
-1 |
-0.85 |
| Weighted Average Shares
Out |
$54.15 M
|
$53.65 M
|
$50.72 M
|
$47.41 M
|
$42.67 M
|
$35.89 M
|
$31.20 M
|
$27.28 M
|
$24.62 M
|
$20.88 M
|
| Weighted Average Shares
Out Diluted |
$54.15 M
|
$53.65 M
|
$50.72 M
|
$47.92 M
|
$42.67 M
|
$35.89 M
|
$31.20 M
|
$27.28 M
|
$24.62 M
|
$20.97 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
